Simplifying Global Compliance
Phase III Failure Bruises Eli Lilly’s Blissful 2014 Outlook
Washington Drug Letter
Eli Lilly’s plans for strong sales growth in 2014 have been set back, with the drugmaker saying Thursday its promising depression treatment edivoxetine has failed in late-stage testing.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing